IXICO secures £3.5M phase 3 trial contract as CEO highlights Huntington’s research momentum

Proactive - Interviews for investors

IXICO Plc CEO Bram Goorden joined Steve Darling from Proactive to discuss a major milestone for the company, announcing the signing of a new commercial agreement with a global pharmaceutical partner. Under the contract, IXICO will deliver its specialized neuroimaging services for a worldwide Phase 3 clinical trial in Huntington’s disease (HD)—a deal valued at more than £3.5 million over four years. Goorden explained that this partnership underscores IXICO’s established reputation as a leading provider of advanced imaging solutions in neurological drug development. The company’s work will support one of the most significant late-stage studies currently underway in Huntington’s disease, a condition that continues to see growing investment and scientific progress. He highlighted that momentum in Huntington’s disease research is accelerating, driven by promising therapeutic candidates and a strengthened commitment across the industry to address this devastating rare disorder. HD is an inherited neurodegenerative disease that causes the gradual destruction of nerve cells in the brain, leading to profound impacts on motor coordination, cognition, behaviour, and emotional health. With no cure and limited treatment options, advances in clinical research are crucial for patients and families affected by the condition. IXICO brings a deep and well-recognized expertise to Huntington’s disease clinical trials. The company has been an active and respected contributor to the global HD research ecosystem for more than a decade. Goorden noted that IXICO’s strengths—including its highly refined HD imaging biomarkers, sophisticated trial management capabilities, and state-of-the-art image analysis technology—continue to make it a partner of choice for pharmaceutical sponsors pursuing next-generation therapies. He added that the new contract not only reflects confidence in IXICO’s technical capabilities but also reinforces the company’s role as a key enabler of scientific progress in rare neurological diseases. #proactiveinvestors #ixicoplc #aim #ixi #neuroscience